Sanofi misled investors with rosy Lemtrada predictions, lawsuit alleges

Save

Sanofi investors are fed up with disappointing news on the multiple sclerosis drug Lemtrada. Vaunted as a potential blockbuster, the drug hasn't even made it to market in the U.S. Now, some investment funds are suing the French drugmaker, saying executives talked up Lemtrada in public–and kept bad news from the FDA private.